Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning
Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic...
Saved in:
| Published in | Clinical therapeutics Vol. 42; no. 8; pp. 1467 - 1482.e4 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.08.2020
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2).
Studies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18–75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7–9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10–14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1–3. The PK properties (Cmax, AUC0–last, and AUC0–∞) of edaravone and its sulfate conjugate metabolite were measured.
In study 1, the geometric least-squares mean (GLSM) Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC0–last, AUC0–∞, unbound AUC from time zero to infinity, and Cmax of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study.
Mild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment).
•Hepatic impairment had no effect on edaravone PK in Japanese and white subjects•There were no notable safety concerns with edaravone administration•Edaravone dosage adjustments are unlikely to be needed in hepatic impairment•Edaravone PK did not differ in Japanese and white subjects after IV administration |
|---|---|
| AbstractList | AbstractPurposeTwo studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2). MethodsStudies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18–75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7–9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10–14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1–3. The PK properties (C max, AUC 0–last, and AUC 0–∞) of edaravone and its sulfate conjugate metabolite were measured. FindingsIn study 1, the geometric least-squares mean (GLSM) C max and AUC 0–∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM C max and AUC 0–∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC 0–last, AUC 0–∞, unbound AUC from time zero to infinity, and C max of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study. ImplicationsMild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment). Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2). Studies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18–75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7–9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10–14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1–3. The PK properties (Cmax, AUC0–last, and AUC0–∞) of edaravone and its sulfate conjugate metabolite were measured. In study 1, the geometric least-squares mean (GLSM) Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC0–last, AUC0–∞, unbound AUC from time zero to infinity, and Cmax of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study. Mild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment). •Hepatic impairment had no effect on edaravone PK in Japanese and white subjects•There were no notable safety concerns with edaravone administration•Edaravone dosage adjustments are unlikely to be needed in hepatic impairment•Edaravone PK did not differ in Japanese and white subjects after IV administration Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2).PURPOSETwo studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2).Studies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18-75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7-9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10-14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1-3. The PK properties (Cmax, AUC0-last, and AUC0-∞) of edaravone and its sulfate conjugate metabolite were measured.METHODSStudies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18-75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7-9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10-14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1-3. The PK properties (Cmax, AUC0-last, and AUC0-∞) of edaravone and its sulfate conjugate metabolite were measured.In study 1, the geometric least-squares mean (GLSM) Cmax and AUC0-∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM Cmax and AUC0-∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC0-last, AUC0-∞, unbound AUC from time zero to infinity, and Cmax of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study.FINDINGSIn study 1, the geometric least-squares mean (GLSM) Cmax and AUC0-∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM Cmax and AUC0-∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC0-last, AUC0-∞, unbound AUC from time zero to infinity, and Cmax of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study.Mild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment).IMPLICATIONSMild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment). PurposeTwo studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2).MethodsStudies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18–75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7–9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10–14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1–3. The PK properties (Cmax, AUC0–last, and AUC0–∞) of edaravone and its sulfate conjugate metabolite were measured.FindingsIn study 1, the geometric least-squares mean (GLSM) Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM Cmax and AUC0–∞ of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC0–last, AUC0–∞, unbound AUC from time zero to infinity, and Cmax of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study.ImplicationsMild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment). Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2). Studies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18-75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7-9 (n = 6); or normal hepatic functioning (n = 8). In study 2, subjects had severe hepatic impairment (Child-Pugh score 10-14; n = 6) or normal hepatic functioning (n = 6). In both studies, all subjects were given edaravone 30 mg IV infused over 60 min on the morning of day 1. Blood samples for use in PK analyses were collected from days 1-3. The PK properties (C , AUC , and AUC ) of edaravone and its sulfate conjugate metabolite were measured. In study 1, the geometric least-squares mean (GLSM) C and AUC of unchanged edaravone were 1.203- and 1.065-fold greater, respectively, in subjects with mild hepatic impairment versus normal hepatic functioning, and were 1.235- and 1.142-fold greater, respectively, in subjects with moderate hepatic impairment versus normal hepatic functioning. In study 2, GLSM C and AUC of unchanged edaravone were 1.203- and 1.190-fold greater, respectively, in subjects with severe hepatic impairment versus normal hepatic functioning. In both studies the AUC , AUC , unbound AUC from time zero to infinity, and C of unchanged edaravone were increased slightly with increases in Child-Pugh classification. No adverse events considered related to edaravone were reported, except for 1 case of sinus bradycardia in a subject with normal hepatic functioning in study 2. The event was moderate in severity, considered as possibly related to edaravone, and resolved during the study. Mild to moderate and severe hepatic impairment had no apparent clinically significant effects on the PK profile of edaravone in Japanese and white subjects, respectively, relative to individuals with normal hepatic functioning, and there were no notable tolerability concerns. Thus, edaravone dosage adjustments are unlikely to be needed in edaravone-treated patients with mild to moderate and severe hepatic impairment. ClinicalTrials.gov identifiers: NCT03289234 (mild to moderate hepatic impairment) and NCT03664544 (severe hepatic impairment). |
| Author | Nakamaru, Yoshinobu Akimoto, Makoto Todorovic, Vesna Greis, Thomas Yoshida, Kaori Kakubari, Masae Kondo, Kazuoki |
| Author_xml | – sequence: 1 givenname: Yoshinobu surname: Nakamaru fullname: Nakamaru, Yoshinobu email: nakamaru.yoshinobu@mf.mt-pharma.co.jp organization: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan – sequence: 2 givenname: Masae surname: Kakubari fullname: Kakubari, Masae organization: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan – sequence: 3 givenname: Kaori surname: Yoshida fullname: Yoshida, Kaori organization: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan – sequence: 4 givenname: Makoto surname: Akimoto fullname: Akimoto, Makoto organization: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan – sequence: 5 givenname: Vesna orcidid: 0000-0001-8001-3570 surname: Todorovic fullname: Todorovic, Vesna organization: Mitsubishi Tanabe Pharma Europe Ltd, London, United Kingdom – sequence: 6 givenname: Thomas surname: Greis fullname: Greis, Thomas organization: Mitsubishi Tanabe Pharma Europe Ltd, London, United Kingdom – sequence: 7 givenname: Kazuoki surname: Kondo fullname: Kondo, Kazuoki organization: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32800532$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstuEzEUtVARfcAvgCU2LDLBj3kuAFVRSyu1FClddGc5njvEqccOtieoX8bv4SFtFpEQXdm6Oufcc-89x-jAOgsIvaNkSgktP66mymgbl-DllBFGpqScpvoLdETrqskoze8O0BGheZOxhtaH6DiEFSGENwV7hQ45qwkpODtCv2_WYDMjF2AmeK7tDwNZ6wLgeRxaDQG7Dqc2-PtS-l4qd68tRK3-1s9a6eUmGcPa4vmwWIGKAf_ScYmvtWkn-Nq1yWCECXYez2EDHvAFrGUSwJf9Wmrfg4145tLfQ4uj25P55lJTs-OcD1ZF7Wyy-Rq97KQJ8ObxPUG352e3s4vs6ubr5ez0KlMFJTGr6pYzrpqqqFnDikUhm5IQBcBpV1LGu0oVC1aD5DWrCJU1dKrqGCvKjtBO8hP0YSu79u7nACGKXgcFxkgLbgiC5TyvirTWKkHf70FXbvA2mUuoPCd1RYs8od4-ooZFD61Ye91L_yCeLpIAn7YA5V0IHjqhdJTj1NFLbQQlYkyAWIldAsSYAEFKkeqJX-3xn1r8n3m6ZULa50aDF0FpsApa7dNJROv0MzQ-72mMOK2kuYcHCLuNUBGYIGI-JnQMKCOccFbeJYEv_xZ4loU_Ug38Ew |
| CitedBy_id | crossref_primary_10_1089_adt_2021_005 crossref_primary_10_1002_cpdd_952 crossref_primary_10_1016_j_clinthera_2023_09_025 crossref_primary_10_1038_s41598_025_92605_5 crossref_primary_10_1002_cpdd_925 |
| Cites_doi | 10.1007/s40262-018-0655-4 10.1080/21678421.2017.1353100 10.1016/j.clinthera.2018.08.009 10.1111/j.1872-034X.2010.00751.x 10.1007/s00228-008-0553-z 10.1124/dmd.106.013912 10.1007/s10157-008-0108-8 10.1007/s10157-007-0495-2 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Inc. Elsevier Inc. Copyright © 2020 Elsevier Inc. All rights reserved. 2020. Elsevier Inc. |
| Copyright_xml | – notice: 2020 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2020 Elsevier Inc. All rights reserved. – notice: 2020. Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2020.06.016 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 1482.e4 |
| ExternalDocumentID | 32800532 10_1016_j_clinthera_2020_06_016 S014929182030326X 1_s2_0_S014929182030326X |
| Genre | Multicenter Study Controlled Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c510t-78d323c97582925b5a9600cee31f6123f7c5b28ea382701a8efc7f2256f01fa3 |
| IEDL.DBID | 7X7 |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Thu Jul 10 22:05:36 EDT 2025 Wed Aug 13 10:35:11 EDT 2025 Mon Jul 21 05:51:00 EDT 2025 Thu Apr 24 23:12:00 EDT 2025 Tue Jul 01 04:21:53 EDT 2025 Fri Feb 23 02:47:29 EST 2024 Tue Feb 25 19:59:20 EST 2025 Tue Aug 26 16:32:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | hepatic insufficiency pharmacokinetics mild–moderate edaravone severe tolerability |
| Language | English |
| License | Copyright © 2020 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-78d323c97582925b5a9600cee31f6123f7c5b28ea382701a8efc7f2256f01fa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0001-8001-3570 |
| PMID | 32800532 |
| PQID | 2444087154 |
| PQPubID | 1226358 |
| ParticipantIDs | proquest_miscellaneous_2434750397 proquest_journals_2444087154 pubmed_primary_32800532 crossref_citationtrail_10_1016_j_clinthera_2020_06_016 crossref_primary_10_1016_j_clinthera_2020_06_016 elsevier_sciencedirect_doi_10_1016_j_clinthera_2020_06_016 elsevier_clinicalkeyesjournals_1_s2_0_S014929182030326X elsevier_clinicalkey_doi_10_1016_j_clinthera_2020_06_016 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-01 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Center for Drug Evaluation and Research (bib4) 2016 bib14 Büdingen, Gonzalez, Tucker, Derendorf (bib16) 2014; 2 Verbeeck (bib15) 2008; 64 Nakamaru, Kakubari, Yoshida, Akimoto, Kondo (bib13) 2020 Mizuno, Takahashi, Iwase, Kusuhara, Niwa, Sugiyama (bib17) 2007; 35 (bib10) February 17, 2005 (bib11) 2017 Dash, Babu, Srinivas (bib3) 2018; 57 bib8 US Food and Drug Administration (bib9) May 2003 Nakamaru, Kinoshita, Kawaguchi (bib1) 2017; 18 Wang, Chen, Yuan (bib2) 2018; 40 Hishida (bib7) 2007; 11 Hishida (bib6) 2009; 13 Imai, Yasuda, Makino (bib12) 2011; 54 Hirano (bib5) 2011; 41 Hishida (10.1016/j.clinthera.2020.06.016_bib7) 2007; 11 (10.1016/j.clinthera.2020.06.016_bib11) 2017 Imai (10.1016/j.clinthera.2020.06.016_bib12) 2011; 54 Wang (10.1016/j.clinthera.2020.06.016_bib2) 2018; 40 Verbeeck (10.1016/j.clinthera.2020.06.016_bib15) 2008; 64 Mizuno (10.1016/j.clinthera.2020.06.016_bib17) 2007; 35 Büdingen (10.1016/j.clinthera.2020.06.016_bib16) 2014; 2 Nakamaru (10.1016/j.clinthera.2020.06.016_bib1) 2017; 18 Nakamaru (10.1016/j.clinthera.2020.06.016_bib13) 2020 Center for Drug Evaluation and Research (10.1016/j.clinthera.2020.06.016_bib4) 2016 Hirano (10.1016/j.clinthera.2020.06.016_bib5) 2011; 41 Dash (10.1016/j.clinthera.2020.06.016_bib3) 2018; 57 Hishida (10.1016/j.clinthera.2020.06.016_bib6) 2009; 13 US Food and Drug Administration (10.1016/j.clinthera.2020.06.016_bib9) 2003 |
| References_xml | – ident: bib14 article-title: Radicava (edaravone) injection, for intravenous use – year: 2016 ident: bib4 article-title: Radicava (Edaravone) Injection. Clinical Pharmacology and Biopharmaceutics Review(s) – year: 2020 ident: bib13 article-title: An open-label, single-dose study to evaluate the pharmacokinetic variables of edaravone in participants with mild, moderate, or no renal impairment. publication-title: Clin Ther – volume: 2 start-page: 17 year: 2014 end-page: 42 ident: bib16 article-title: Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments publication-title: Ther Adv Infect Dis – volume: 57 start-page: 1385 year: 2018 end-page: 1398 ident: bib3 article-title: Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics publication-title: Clin Pharmacokinet – volume: 54 start-page: 403 year: 2011 end-page: 405 ident: bib12 article-title: Japan association of chronic kidney disease initiatives publication-title: JMAJ – volume: 35 start-page: 1429 year: 2007 end-page: 1434 ident: bib17 article-title: Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate publication-title: Drug Metab Dispos – year: May 2003 ident: bib9 article-title: Guidance for Industry—Pharmacokinetics in Patients with Impaired Hepatic Function—Study Design, Data Analysis, and Impact on Dosing and Labeling – volume: 64 start-page: 1147 year: 2008 end-page: 1161 ident: bib15 article-title: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction publication-title: Eur J Clin Pharmacol – year: 2017 ident: bib11 article-title: Radicava (Edaravone) Injection – volume: 18 start-page: 80 year: 2017 end-page: 87 ident: bib1 article-title: Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 11 start-page: 292 year: 2007 end-page: 296 ident: bib7 article-title: Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance publication-title: Clin Exp Nephrol – ident: bib8 article-title: Radicut – year: February 17, 2005 ident: bib10 article-title: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic functioning – volume: 41 start-page: 142 year: 2011 end-page: 150 ident: bib5 article-title: Clinical evaluation of liver injury in patients with acute ischemic brain stroke treated with edaravone publication-title: Hepatol Res – volume: 13 start-page: 118 year: 2009 end-page: 122 ident: bib6 article-title: Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone publication-title: Clin Exp Nephrol – volume: 40 start-page: 1683 year: 2018 end-page: 1691 ident: bib2 article-title: Bioavailability of edaravone sublingual tablet versus intravenous infusion in healthy male volunteers publication-title: Clin Ther – volume: 57 start-page: 1385 year: 2018 ident: 10.1016/j.clinthera.2020.06.016_bib3 article-title: Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics publication-title: Clin Pharmacokinet doi: 10.1007/s40262-018-0655-4 – year: 2017 ident: 10.1016/j.clinthera.2020.06.016_bib11 – year: 2020 ident: 10.1016/j.clinthera.2020.06.016_bib13 article-title: An open-label, single-dose study to evaluate the pharmacokinetic variables of edaravone in participants with mild, moderate, or no renal impairment. publication-title: Clin Ther – volume: 18 start-page: 80 issue: suppl 1 year: 2017 ident: 10.1016/j.clinthera.2020.06.016_bib1 article-title: Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1353100 – volume: 40 start-page: 1683 year: 2018 ident: 10.1016/j.clinthera.2020.06.016_bib2 article-title: Bioavailability of edaravone sublingual tablet versus intravenous infusion in healthy male volunteers publication-title: Clin Ther doi: 10.1016/j.clinthera.2018.08.009 – volume: 41 start-page: 142 year: 2011 ident: 10.1016/j.clinthera.2020.06.016_bib5 article-title: Clinical evaluation of liver injury in patients with acute ischemic brain stroke treated with edaravone publication-title: Hepatol Res doi: 10.1111/j.1872-034X.2010.00751.x – volume: 64 start-page: 1147 year: 2008 ident: 10.1016/j.clinthera.2020.06.016_bib15 article-title: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-008-0553-z – volume: 2 start-page: 17 year: 2014 ident: 10.1016/j.clinthera.2020.06.016_bib16 article-title: Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments publication-title: Ther Adv Infect Dis – year: 2003 ident: 10.1016/j.clinthera.2020.06.016_bib9 – volume: 54 start-page: 403 year: 2011 ident: 10.1016/j.clinthera.2020.06.016_bib12 article-title: Japan association of chronic kidney disease initiatives publication-title: JMAJ – volume: 35 start-page: 1429 year: 2007 ident: 10.1016/j.clinthera.2020.06.016_bib17 article-title: Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.013912 – volume: 13 start-page: 118 year: 2009 ident: 10.1016/j.clinthera.2020.06.016_bib6 article-title: Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone publication-title: Clin Exp Nephrol doi: 10.1007/s10157-008-0108-8 – volume: 11 start-page: 292 year: 2007 ident: 10.1016/j.clinthera.2020.06.016_bib7 article-title: Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance publication-title: Clin Exp Nephrol doi: 10.1007/s10157-007-0495-2 – year: 2016 ident: 10.1016/j.clinthera.2020.06.016_bib4 |
| SSID | ssj0003952 |
| Score | 2.3414018 |
| Snippet | Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic... AbstractPurposeTwo studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to... PurposeTwo studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1467 |
| SubjectTerms | Adolescent Adult Aged Amyotrophic lateral sclerosis Area Under Curve Birth control Body mass index Bradycardia Bradycardia - chemically induced Cytochrome Disease Dosage Drug dosages edaravone Edaravone - adverse effects Edaravone - blood Edaravone - pharmacokinetics FDA approval Female Free Radical Scavengers - adverse effects Free Radical Scavengers - blood Free Radical Scavengers - pharmacokinetics hepatic insufficiency Humans Internal Medicine Liver Liver Diseases - blood Liver Diseases - metabolism Male Medical Education Medical laboratories Metabolites Middle Aged mild–moderate Neuroprotective Agents - adverse effects Neuroprotective Agents - blood Neuroprotective Agents - pharmacokinetics Pharmacokinetics severe Sulfates tolerability Urine Vital signs Young Adult |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhh9JLadPXpmlRoeRkdWVJfvVWlizbwoZAtrA34ZUlcGvssN4Ucunf6t_rjC17SZuSQo_r1ciyHt-MpG9mCHkHKjVVLhPM8FQxJQrJsrzIWOgwzUMiM9WxKpfn8eKL-ryO1gdkNvjCIK3SY3-P6R1a-ydT35vTq7KcIi0JdDsGIAcYFvEaPdhVgrP8_Y89zUNmXdYdLMyw9C2OF3ofdn5OsFEUvAvkiYnP79ZQf7NAO000f0weeROSfuxb-YQc2PqIPFj6S_IjcnrRh6O-Cehq713VBvSUXuwDVd88JT-RTcJgGtgqoJegwyrLiqa11JMLaeMotHuU-gbVY034_KzIt_n3pra0rCmgDx7ntBRPdemyrIqAdknWwJANaLOllxZWjKULi_xtQz8BBpVbPJekM8-Bp7vmt2rO0ZquRpk5KGB_ePyMrOZnq9mC-UQOzMCS37EkLaSQJoO9ichEtIly2DdxUM8ydBj-xSUm2ojU5jIVCQ_z1DqTOECa2PHQ5fI5Oazhg14SaoSV1kSgYSWo3zTLjRR2o7gtZMJdriYkHsZOGx_kHHNtVHpgs33V46BrHHSNvL4wnhA-Cl71cT7uF0mHyaEHN1YAXg266H7R5C5R23oAaXWoW6G5_mOST8iHUfLWOvm3154Mc1iPbwL7TnHYNkfQeW_HvwFk8OYor21zjWWkwgvvLJmQF_3cH3tJihSRXBz_T8tekYf4q2dWnpDD3fbavgZrb7d50y3nX2foVEk priority: 102 providerName: Elsevier |
| Title | Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S014929182030326X https://www.clinicalkey.es/playcontent/1-s2.0-S014929182030326X https://dx.doi.org/10.1016/j.clinthera.2020.06.016 https://www.ncbi.nlm.nih.gov/pubmed/32800532 https://www.proquest.com/docview/2444087154 https://www.proquest.com/docview/2434750397 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeEIyPBUZlJLSnGBw7aWJe0JhadaBWFStS36zUcaRClIymQ9oL_xb_HneJkwo0GE-V0p6TxuffffjnO0JegUlNwlwJZngSslBkkqk0UyzIsc1DLFXYsCqns-Hkc_hhGS1dwq12tMoOExugziqDOfI3YIZCDt59FL67_MawaxTurroWGnvkAEuXIaUrXvYBF5eq6biDUQATKkh-43fhycPmjBMEiYI3RTyx6fnN1ulv3mdjhcYPyH3nPtLTdr4fkju2PCR3p26D_JCczNtS1Nc-XexOVtU-PaHzXZHq60fkJzJJGKiALXx6AfarsCyraksdsZBWOYXn7qW-wvA4El4fZekm_V6Vlq5LCsiDqZyaYkaXTtdF5tOmwRo4sT6tNvTCwmqxdGKRu23oOeDPeoM5SXrm-O90W_0xzAw96aKXGYPxdYnjx2QxHi3OJsw1cWAGlvuWxUkmhTQK4hKhRLSKUoiZOJhmGeRY-iWPTbQSiU1lImIepInNTZwDygxzHuSpfEL2S_hDR4QaYaU1EVhXCaY3UamRwq5CbjMZ8zwNPTLs5k4bV-Ac-2wUumOyfdH9pGucdI2cvmDoEd4LXrY1Pm4XSTrl0N0RVgBdDXbodtH4JlFbO_CodaBroXnDu1OotgKAGLzspUfe9pLOP2r9nv-77XGnw7q_025ReeRl_zUADO4apaWtrvA3MsTNbhV75Gmr-_1bkiJBFBfP_j34c3IPn6TlTR6T_e3myr4AX267GpC91z-CQbNsB-Tg9PzjZAaf70ez-adfTwhNXQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTgJeEIxfgQFGgj3VWmInTYyEEIxWLVurihWpb1bqOFKhakbTgfpH8cy_x11-VaDBeNlrmnOS-nzfZ_vzHcALhNTIT5Xgxo187otEchUninsplXkIpfILVeVw1Ol_8j9Mg-kO_KjPwpCsso6JRaBOMkNr5IcIQ76L7D7w35x95VQ1inZX6xIapVsc2813nLLlrwfvsX9fCtHrTo76vKoqwA3635qHUSKFNAqJslAimAUxkngXsUJ6KeUiSUMTzERkYxmJ0PXiyKYmTNHtO6nrpbHEZq_Bri9xJtOC3Xfd0fhjE_qlKkr80LSDC-VFvwnK6KhjcagKZ6XCLbKGUpX1i-Hwb3S3gL3ebbhV8VX2tnSwO7Bjl3twfVjtyO_BwbjMfb1ps8n2KFfeZgdsvM2KvbkLP0m6wtHn7KLNThEwF5YnWW5ZpWRkWcrwvRurL9g8tUTXu0m8ir9lS8vmS4ahjtaOckZLyGw4XyRtVlR0Q9bcZtmKnVocnpb1LYnFDRtgwJuvaBGUHVWCe7bO_mhmRNR90dj0EO2rlep7MLmK_r0PrSV-0ENgRlhpTYBwLhHrIxUbKezMd20iQzeNfQc6dd9pU2VUp8IeC11L5z7rptM1dbomEaHXccBtDM_KpCKXm0S1c-j6zCxGeY3Ad7lpeJGpzatolWtP50K7hdBPkdsKjPxI66cOvGosK0JWEq3_e-x-7cO6edJ2FDvwvPkZIxptU8VLm53TPdKn3XUVOvCg9P3mX5IiItgQj_7d-DO40Z8MT_TJYHT8GG7SW5WizX1orVfn9gkSyfXsaTV8GegrDhi_AMsXhaw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLXGkCZeEIyPFQYYCfYUa46dNDESmqZtVctoVWlF6puVOrZUqJLRdKD-MsS_4958VaDBeNlrmusk9fU9x_bxvYS8AUiNA6cEMzwOWCBSyVSSKuY7LPMQSRWUqsrhqNv_FHyYhtMt8rM5C4OyyiYmloE6zQ2ukR8CDAUc2H0YHLpaFjE-7R1dfmVYQQp3WptyGpWLnNv1d5i-Fe8Hp9DXb4XonU1O-qyuMMAM-OKKRXEqhTQKSLNQIpyFCRB6DrghfYd5SVxkwpmIbSJjEXE_ia0zkYMh0HXcd4mEZu-Qu5EMfRxi0bSd63GpymI_OAFhQvnxb9IyPPRYHq-C-angZf5QrLd-PTD-jfiWANh7QO7XzJUeV672kGzZbJfsDOu9-V1yMK6yYK89Otkc6io8ekDHm_zY60fkB4pYGHifXXj0AqBzYVmaF5bWmkaaOwrv3Vp9geaxJbx-libL5FueWTrPKAQ9XEUqKC4m0-F8kXq0rO0G_Nmj-ZJeWBiolvYtysYNHUDomy9xOZSe1NJ7usr_aGaEJH7R2vQA9-s168dkchu9-4RsZ_BBe4QaYaU1IQC7BNSPVWKksLOA21RG3CVBh3SbvtOmzq2OJT4WuhHRfdZtp2vsdI1yQr_bIbw1vKzSi9xsEjfOoZvTsxDvNUDgzabRdaa2qONWoX1dCM1LyZ9CtxWAAUDwpx3yrrWsqVlFuf7vsfuND-v2SZvx3CGv258htuGGVZLZ_ArvkQHus6uoQ55Wvt_-S1LECCDi2b8bf0V2IEzoj4PR-XNyD1-qUm_uk-3V8sq-AEa5mr0sxy4l-pZjxS90DYh8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Open-label%2C+Single-dose+Studies+of+the+Pharmacokinetics+of+Edaravone+in+Subjects+with+Mild%2C+Moderate%2C+or+Severe+Hepatic+Impairment+Compared+to+Subjects+with+Normal+Hepatic+Functioning&rft.jtitle=Clinical+therapeutics&rft.au=Nakamaru%2C+Yoshinobu&rft.au=Kakubari%2C+Masae&rft.au=Yoshida%2C+Kaori&rft.au=Akimoto%2C+Makoto&rft.date=2020-08-01&rft.eissn=1879-114X&rft.volume=42&rft.issue=8&rft.spage=1467&rft_id=info:doi/10.1016%2Fj.clinthera.2020.06.016&rft_id=info%3Apmid%2F32800532&rft.externalDocID=32800532 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291820X00099%2Fcov150h.gif |